Reaction: Valbenazine to 1 product

Reaction
Valbenazine
DB11915
    [+]-α-HTBZ
    DBMET01448
    Reaction type
    hydrolysis
    Direction
    Major circulating metabolite?
    Yes
    Spontaneous?
    No
    Activity
    active
    References
    1. Grigoriadis DE, Smith E, Hoare SRJ, Madan A, Bozigian H: Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites. J Pharmacol Exp Ther. 2017 Jun;361(3):454-461. doi: 10.1124/jpet.116.239160. Epub 2017 Apr 12. [Article]
    2. Harriott ND, Williams JP, Smith EB, Bozigian HP, Grigoriadis DE: VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine). Prog Med Chem. 2018;57(1):87-111. doi: 10.1016/bs.pmch.2017.12.002. Epub 2018 Mar 7. [Article]
    3. Wang W, Du G, Lin S, Liu J, Yang H, Yu D, Ye L, Zou F, Wang H, Zhang R, Tian J: (+)-9-Trifluoroethoxy-alpha-Dihydrotetrabenazine as a Highly Potent Vesicular Monoamine Transporter 2 Inhibitor for Tardive Dyskinesia. Front Pharmacol. 2021 Dec 7;12:770377. doi: 10.3389/fphar.2021.770377. eCollection 2021. [Article]
    4. Schneider F, Bradbury M, Baillie TA, Stamler D, Hellriegel E, Cox DS, Loupe PS, Savola JM, Rabinovich-Guilatt L: Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV-50717) Compared With Tetrabenazine in Healthy Volunteers. Clin Transl Sci. 2020 Jul;13(4):707-717. doi: 10.1111/cts.12754. Epub 2020 Mar 10. [Article]
    5. FDA Approved Drug Products: INGREZZA® (valbenazine) capsules, for oral use (August 2023) [Link]
    Comments
    Not Available
    Enzymes
    Not Available